Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

Por Farnier, Michel, Dong, Qian, Shah, Arvind, Johnson-Levonas, Amy O, Brudi, Philippe
Publicado em 2011

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with...

Por Farnier, Michel, Chen, Erluo, Johnson-Levonas, Amy O, McCrary Sisk, Christine, Mitchel, Yale B
Publicado em 2014

Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin

Por Krauss, Ronald M., Pinto, Cathy Anne, Liu, Yang, Johnson-Levonas, Amy O., Dansky, Hayes M.
Publicado no J Clin Lipidol (2014)

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

Por Brinton, Eliot A., Triscari, Joseph, Brudi, Philippe, Chen, Erluo, Johnson-Levonas, Amy O., Sisk, Christine McCrary, Ruck, Rae Ann, MacLean, Alexandra A., Maccubbin, Darbie, Mitchel, Yale B.
Publicado no Lipids Health Dis (2016)

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib

Por Krauss, Ronald M., Wojnooski, Kathleen, Orr, Joseph, Geaney, J. Casey, Pinto, Cathy Anne, Liu, Yang, Wagner, John A., Luk, Julie Mabalot, Johnson-Levonas, Amy O., Anderson, Matt S., Dansky, Hayes M.
Publicado em 2012

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

Por Wagner, Andrew J., Banerji, Udai, Mahipal, Amit, Somaiah, Neeta, Hirsch, Heather, Fancourt, Craig, Johnson-Levonas, Amy O., Lam, Raymond, Meister, Amy K., Russo, Giuseppe, Knox, Clayton D., Rose, Shelonitda, Hong, David S.
Publicado no J Clin Oncol (2017)

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

Por Bays, Harold E, Brinton, Eliot A, Triscari, Joseph, Chen, Erluo, Maccubbin, Darbie, MacLean, Alexandra A, Gibson, Kendra L, Ruck, Rae Ann, Johnson-Levonas, Amy O, O’Neill, Edward A, Mitchel, Yale B
Publicado no Vasc Health Risk Manag (2015)

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

Por Ravandi, Farhad, Gojo, Ivana, Patnaik, Mrinal M., Minden, Mark D., Kantarjian, Hagop, Johnson-Levonas, Amy O., Fancourt, Craig, Lam, Raymond, Jones, Mary Beth, Knox, Clayton D., Rose, Shelonitda, Patel, Payal Shah, Tibes, Raoul
Publicado no Leuk Res (2016)

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

Por Krishna, Rajesh, Addy, Carol, Tatosian, Daniel, Glasgow, Xiaoli S., Gendrano III, Isaias Noel, Robberechts, Martine, Haazen, Wouter, de Hoon, J.N., Depré, Marleen, Martucci, Ashley, Peng, Joanna Z., Johnson‐Levonas, Amy O., Wagner, John A., Stoch, S. Aubrey
Publicado no J Clin Pharmacol (2016)

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

Por Thomas, Tiffany, Zhou, Haihong, Karmally, Wahida, Ramakrishnan, Rajasekhar, Holleran, Stephen, Liu, Yang, Jumes, Patricia, Wagner, John A., Hubbard, Brian, Previs, Stephen F., Roddy, Thomas, Johnson-Levonas, Amy O., Gutstein, David E., Marcovina, Santica M., Rader, Daniel J., Ginsberg, Henry N., Millar, John S., Reyes-Soffer, Gissette
Publicado no Arterioscler Thromb Vasc Biol (2017)

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

Por Millar, John S., Reyes-Soffer, Gissette, Jumes, Patricia, Dunbar, Richard L., deGoma, Emil M., Baer, Amanda L., Karmally, Wahida, Donovan, Daniel S., Rafeek, Hashmi, Pollan, Laura, Tohyama, Junichiro, Johnson-Levonas, Amy O., Wagner, John A., Holleran, Stephen, Obunike, Joseph, Liu, Yang, Ramakrishnan, Rajasekhar, Lassman, Michael E., Gutstein, David E., Ginsberg, Henry N., Rader, Daniel J.
Publicado no J Clin Invest (2015)

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

Por Millar, John S., Reyes-Soffer, Gissette, Jumes, Patricia, Dunbar, Richard L., deGoma, Emil M., Baer, Amanda L., Karmally, Wahida, Donovan, Daniel S., Rafeek, Hashmi, Pollan, Laura, Tohyama, Junichiro, Johnson-Levonas, Amy O., Wagner, John A., Holleran, Stephen, Obunike, Joseph, Liu, Yang, Ramakrishnan, Rajasekhar, Lassman, Michael E., Gutstein, David E., Ginsberg, Henry N., Rader, Daniel J.
Publicado no J Clin Invest (2016)

CETP inhibition with Anacetrapib Decreases Fractional Clearance Rates of HDL Apolipoprotein A-I and Plasma CETP

Por Reyes-Soffer, Gissette, Millar, John S., Ngai, Colleen, Jumes, Patricia, Coromilas, Ellie, Asztalos, Bela, Johnson-Levonas, Amy O., Wagner, John A., Donovan, Daniel S., Karmally, Wahida, Ramakrishnan, Rajasekhar, Holleran, Stephen, Thomas, Tiffany, Dunbar, Richard L., deGoma, Emil M., Rafeek, Hashmi, Baer, Amanda L., Liu, Yang, Lassman, Michael E., Gutstein, David E., Rader, Daniel J., Ginsberg, Henry N.
Publicado no Arterioscler Thromb Vasc Biol (2016)